Amber Ratcliffe was close to graduating with her MBA in 2003 and had accepted a job offer at an established Seattle biotech firm when she submitted her plan for NanoString to the UW Business Plan Competition. To her amazement, her plan for the life sciences start-up won the grand prize, the “Best High-Tech Idea” award and $31,000 in start-up capital, leaving Ratcliffe with a big decision to make.
“I wasn’t going to live my life wondering what might have been,” she said. So she changed course, put the entrepreneurial strategies she’d learned at Foster into practice, and co-founded NanoString Technologies in June 2003. NanoString commercialized an innovative technology invented at the Institute for Systems Biology to use DNA barcodes to detect and count molecules in biological samples. It might sound like science fiction, but the technology is now helping researchers at organizations like the National Cancer Institute gain a better understanding of how to battle cancer.
“Researchers, like entrepreneurs, want to solve the problems that no one else has been able to crack,” said Ratcliffe, who is now the company’s director of marketing. “Foster gave me the tools to be an entrepreneur and now NanoString is giving scientists the tools to conduct studies that were previously inconceivable. It’s an exciting and rewarding combination.”
Her decision to take a chance on NanoString has been validated: the company has been shipping products internationally since 2008 and has raised over $47 million in venture capital. The next big challenge for NanoString is the competitive clinical diagnostic market. “NanoString’s combination of features are very well suited for this new market,” Ratcliffe said. “We believe this technology has the potential to make a significant contribution to the practice of medicine.”